Silver Book Fact

A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took alendronate. The study followed about 1,200 women with low bone mass for over a year.

Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate. http://www.rheumatology.org/press/2008/2008_press_14.asp. Published October 2008

Reference

Title
Direct Comparison of Changes in Bone Density and Bone Turnover Markers in Postmenopausal Women With Low Bone Mass Treated With 6-monthly Denosumab or Weekly Alendronate
Publication Date
Published October 2008
Authors
Deal, Chad, Jacques Brown, Robert Recker, Richard Prince, Douglas Kiel, Jose Ã?lvaro-Gracia, Luiz de Gregorio, Peyman Hadji, Lorenz Hofbauer, Huei Wang, Matthew Austin, Richard Newmark, Cesar Libanati, Rachel Wagman, Javier San Martin, Henry Bone
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • 50% of Repeat Osteoporotic Fractures Could be Avoided
     
  • Ibandronate, a bisphosphonate, taken daily has been shown to reduce the risk of new vertebral fractures by around 62%.  
  • Treatment with zoledronic acid over a 3-year period reduced risk of vertebral fracture by around 70% and risk of hip fracture by 41%, and increased bone mineral density (BMD) by…